$TPVG

Is TriplePoint Venture Growth BDC (TPVG) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 13, 2025, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is TriplePoint Venture Growth BDC (TPVG) Stock Undervalued Right Now? — source image
Decision brief

The 30-second read

$TPVGBullishMed
01

Why it matters

If the undervaluation persists, there could be a catalyst for price appreciation; however, market volatility and sector risks could offset gains.

02

Market read

The article's insights are relevant for investors focusing on alternative asset managers and BDCs, with moderate impact on related financial sectors.

03

What to watch

Potential macroeconomic headwinds, rising interest rates, and sector-specific risks could negatively impact TPVG's valuation and performance.

Relevance 6/10Timing: The article was published on 2025-10-13, with relevance for short to medium-term trading horizons.

Background

TPVG is a venture growth BDC that invests in early-stage and growth-stage companies, with valuation metrics suggesting undervaluation.

Company-level read

Ticker impact

$TPVGBullishMedium confidence
Context

The article discusses TriplePoint Venture Growth BDC (TPVG), focusing on its valuation status and potential undervaluation.

Expected impact

Moderate upward price movement over the next 1-3 months, approximately 5-10%.

Evidence & confidence

The analysis is based on valuation trends and earnings estimates, but lacks recent technical confirmation and market sentiment data.

Market effects

As a financial services company, TPVG's valuation could influence investor sentiment in the financial sector, especially among alternative asset managers.

Limited regional impact; primarily relevant to U.S. markets where TPVG operates.

Low; the article's focus is on a U.S.-based venture debt fund.

Counterpoint

Some analysts may view the valuation as overly optimistic, citing potential risks in the venture debt market and interest rate environment.

Key entities

  • TriplePoint Venture Growth BDC

    A Business Development Company focusing on venture debt investments.

  • Zacks Equity Research

    Provider of the article, known for valuation and earnings analysis.

Related articles

$TPVGMed

TriplePoint Venture Growth BDC Q2 Earnings Call Highlights

TriplePoint Venture Growth BDC (TPVG) reported Q2 results on an earnings call. It received $28.6M in loan prepayments and sold Prodigy Investments debt and equity for $43.8M. Total investment income was $22.1M, net investment income $8.3M ($0.21/share). NAV rose to $8.67. Board declared a $0.12 supplemental distribution.

$TPVGMed

TriplePoint Venture Growth BDC Corp. Announces Second Quarter 2026 Financial Results

TriplePoint Venture Growth BDC Corp. (TPVG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TriplePoint Venture Growth BDC Corp. Announces Second Quarter 2026 Financial Results Net Increase in Net Assets Resulting from Operations of $0.26 per Share for the Second Quarter Declares Third Quarter 2026 Regular Distribution of $0.23 per Share and Supplemental Di

$BAMed

Boeing 777F production reportedly halted for nearly two months by supplier dispute

Boeing 777F production halted for nearly two months due to a dispute with supplier Vaero over wing components, costing Boeing up to $6.5M per day. The 777F has 38 unfilled orders, with a backlog of about 31 aircraft. The FAA extended production through 2030, allowing up to 35 additional 777Fs. Boeing delivered 21 777Fs in 2026, with demand continuing despite the transition to the 777-8F.

$LLYMed

Eli Lilly And Company Presents First Clinical Data In Platinum-Sensitive Ovarian Cancer For Its Investigational, Next-Generation, FRa-Targeting ADC At ESMO 2026

Eli Lilly presented Phase 1 data for its investigational ADC sofetabart mipitecan (Sofe-M) plus bevacizumab in platinum-sensitive ovarian cancer, showing a 79% objective response rate and 100% disease control rate. The study included 33 patients, with responses consistent across prior treatments. Sofe-M demonstrated a safety profile consistent with known profiles of each medicine. The company is conducting three global Phase 3 trials for Sofe-M in ovarian cancer.